It’s been nearly one year since the U.S. Food and Drug Administration (FDA) took a major step forward in accelerating multiple myeloma #research. Last April, an FDA advisory committee voted in favor of using minimal residual disease (MRD), a biomarker that detects tiny amounts of #cancer in the body—as a surrogate endpoint for the accelerated approval of new therapies. While final #FDA guidance is still pending, the impact is already being felt across the field. C. Ola Landgren, M.D., Ph.D., who led the pivotal research behind this shift, shares key developments since the ruling, many of which will be explored at the upcoming Miami Myeloma MRD Meeting 2025 on April 11. 🙌 Discover how #MRD is changing the landscape of multiple myeloma care and clinical trial design and paving the way for faster, more targeted drug approvals. https://loom.ly/1v9DO54
MRD must be combined with Chromothripsis to actually measure success or failure of treatment in myeloma....disappearnce of one clone is immaterial if another competitive fitter clone is on the rise.
DataPorium
4d
Sylvester Comprehensive Cancer Center, It's amazing to see how far we've come in multiple myeloma research! The use of MRD as a marker for new therapies sounds like a game changer for patients and their families. Excited to learn more about the upcoming meeting! What are you looking forward to most? 💪✨ #MultipleMyeloma #CancerResearch #MRD
Psychotherapist @ Private Practice | Mental Health Counseling
3dFantastic. So grateful for all you’ve done and continue to do